Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

Studies try to shed light on impact of race

Statistics show lung cancer is the leading cause of cancer death in African-Americans, with 21,550 new cases expected to be diagnosed and 16,700 deaths expected this year.

3 Jun 2007

Oncolytic viruses deliver a knockout punch to cancers

New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers.

11 May 2007

Diabetes drug rosiglitazone boosts power of platinum chemotherapy

A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, scientists from Dana-Farber Cancer Institute report.

8 May 2007

Phenoxodiol, an investigational drug shows promise for ovarian cancer

A new study further supports the unique mechanism of action of phenoxodiol, an investigational drug being studied for the treatment of ovarian cancer.

2 May 2007

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech has announced results of in vitro cytotoxicity and in vivo pharmacokinetic studies conducted to evaluate the potential for combining its phase III anti-cancer antibody therapeutic, Proxinium, with first-line standard of care therapy for squamous cell carcinoma of the head & neck (SCCHN).

19 Apr 2007

Study: Collecting duct carcinoma

Collecting duct carcinoma is a rare and highly aggressive variant of renal cell carcinoma that frequently presents with advanced disease, has few effective treatment options, and is associated with a poor prognosis.

17 Aug 2006

Trial of Topotecan following Carboplatin and Paclitaxel in treatment of ovarian cancer

The drug topotecan does not increase survival for ovarian cancer patients when used with standard chemotherapy in first-line treatment and is not recommended for future use.

2 Aug 2006

FDA gives the green light for Gemzar to treat recurrent ovarian cancer

Drug company Eli Lilly has been given approval by the U.S. Food and Drug Administration (FDA) for its drug Gemzar to be used by women living with recurrent ovarian cancer.

18 Jul 2006

FDA approval for Gemzar for ovarian cancer

Eli Lilly and Company announced that the United States Food and Drug Administration (FDA) has approved Gemzar (gemcitabine HCl) for use in the treatment of women living with recurrent ovarian cancer.

18 Jul 2006

Bortezomib extends lung cancer survival

Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial.

9 Jun 2006

Taxotere combined with standard chemotherapy improves survival in advanced head and neck cancers

The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination.

5 Jun 2006

Risk of secondary malignancies in testicular cancer

While in the United States the preferred treatment for stage I mixed germ cell tumors has been retroperitoneal lymphadenectomy, adjuvant chemotherapy has been more commonly used in Europe.

2 May 2006

New approach to treating breast cancer uses existing chemo drug

British scientists say women who develop breast cancer because of two common genetic mutations could have their treatment transformed by a chemotherapy drug which already exists.

1 May 2006

Single-dose Carboplatin comparable to prophylactic radiotherapy for stage I seminoma

The risk of relapse for patients with stage I seminoma has traditionally ranged between 10 and 15%, depending on the local pathological characteristics of the tumor.

17 Apr 2006

Abdominal chemotherapy boosts survival in ovarian cancer patients

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone

10 Jan 2006

New hope for patients with metastatic melanoma

Patients with metastatic melanoma (MM) have new hope, says a recently published study by Mayo Clinic Cancer Center. The study, which shows the combination of paclitaxel and carboplatin (PC) appears to be effective for MM when traditional treatments have failed, is in this month's issue of Cancer.

6 Jan 2006

Delivering chemotherapy directly into the abdomen boosts survival in ovarian cancer patients

A 50-year-old method for delivering chemotherapy directly into the abdomen is making a comeback as investigators have found that it increases survival - by more than a year - in some women with advanced ovarian cancer. Results from a seven-year study of more than 400 patients nationwide are published in the New England Journal of Medicine.

6 Jan 2006

New treatment for the pediatric eye cancer retinoblastoma

Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.

17 Oct 2005

Giving patients both chemotherapy and radiation in the beginning of treatment may help cancer patients live longer

While researchers have learned in the last decade that combining chemotherapy with radiation is better than radiation alone for treating non-small cell lung cancer patients with locally advanced disease - cancer confined to the lungs - finding the right combination of drugs - and the best timing of treatment - has been tricky.

6 Sep 2005